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Abstract
Background:  Human parvovirus B19 infection has been postulated to the anti-phospholipid
syndrome (APS) in autoimmunity. However, the influence of anti-B19-VP1u antibody in
autoimmune diseases is still obscure.
Methods: To elucidate the effect of anti-B19-VP1u antibodies in systemic lupus erythematosus
(SLE), passive transfer of rabbit anti-B19-VP1u IgG was injected intravenously into NZB/W F1 mice.
Results:  Significant reduction of platelet count and prolonged thrombocytopenia time were
detected in anti-B19-VP1u IgG group as compared to other groups, whereas significant increases
of anti-B19-VP1u, anti-phospholipid (APhL), and anti-double strand DNA (dsDNA) antibody
binding activity were detected in anti-B19-VP1u group. Additionally, significant increases of matrix
metalloproteinase-9 (MMP9) activity and protein expression were detected in B19-VP1u IgG
group. Notably, phosphatidylinositol 3-phosphate kinase (PI3K) and phosphorylated extracellular
signal-regulated kinase (ERK) proteins were involved in the induction of MMP9.
Conclusion: These experimental results firstly demonstrated the aggravated effects of anti-B19-
VP1u antibody in disease activity of SLE.
Background
Human parvovirus B19 (B19) is known as a parvovirus of
human pathogen [1] that consists two structural proteins
including VP1 and VP2, which are identical except for the
227 amino acids at the amino-terminal end of the VP1-
protein, the so-called VP1-unique region (VP1u) [2].
Recently, B19-VP1u has been reported to have the phos-
pholipase A2 (PLA2) motif and secreted phospholipases
A2 (sPLA2) activity [3-6], and is associated with various
autoimmune diseases [7].
The infection of B19 has been postulated to the genera-
tion of various autoantibodies including anti-nuclear
antibody (ANA), anticardiolipin antibody (aCL), and
anti-phospholipid antibody (APhL) [7-11], as well as the
anti-phospholipid syndrome (APS) [8]. Notably, a signif-
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icant similarity existed in the specificity of APhL between
patients with B19 infection or systemic lupus erythemato-
sus (SLE) was reported [9,10]. Recent studies have sug-
gested that B19 may exacerbate or even induce SLE [7,8].
Our recent findings indicated that serum from patients
with acute B19 infection have a high frequency in recog-
nition of cardiolipin (CL) and 2GPI, and the phospholi-
pase domain observed in the B19-VP1u may contribute to
the generation of APhL [12]. Additionally, the BALB/c
mice immunized with anti-B19-VP1u IgG developed
thrombocytopenia, prolongation of aPTT, and autoanti-
body against 2GPI and PhL and suggested the associa-
tion among anti-B19-VP1u IgG and production of anti-
2GPI antibodies, APhL, and APS-like autoimmunity
[13].
However, no further study was performed in elucidating
the effect of anti-B19-VP1u antibody on disease activity in
SLE. In current study, we treated NZB/W F1 mice with pas-
sive transfer of rabbit anti-B19-VP1u antibody to investi-
gate the effect of elicited anti-B19-VP1u antibody on
diseases activity in SLE.
Methods
Preparation of recombinant human B19-VP1 unique 
region protein and rabbit anti-B19-VP1 unique region 
antibody
Construction of B19-VP1u cDNA into pET-32a expression
vector (Novagene, Cambridge, MA) was performed and
the recombinant B19-VP1u protein was purified as
described in our recent publication [12,13]. For genera-
tion of antisera against the B19-VP1u, four female New
Zealand White rabbits were immunized subcutaneous in
the neck region with 0.5 mg of purified recombinant B19-
VP1u protein in Freund's complete adjuvant (Sigma, Saint
Louis Mo, USA) followed by injection at two-week inter-
vals with 0.25 mg of B19-VP1uproteininFreund'sincom-
pleteadjuvant (Sigma, Saint Louis Mo, USA). A control
group were immunized with Freund's complete adjuvant
and followed by injection with Freund's incomplete adju-
vant. All sera reacted specially with the B19-VP1u by
immunoblotting analysis.
Animals and induction of experimental APS by passive 
transfer
Twenty-four female NZB/W F1 mice at age of 8 weeks
were purchased from National Taiwan University, Labora-
tory Animal Center, Taiwan and housed under supervi-
sion of the Institutional Animal Care and Use Committee
at Chung Shan Medical University, Taichung, Taiwan.
Induction of experimental APS by passive transfer was
performed according to the method of Blank [14]. Disease
activity of mice was determined by monitoring the pro-
teinuria biweekly with Albustix test strips from the age of
14 weeks for ten weeks as described previously [15]. All
rabbit IgG were isolated using Protein A beads as
described in our recent report [13,16]. The dosage of anti-
B19-VP1u IgG is based on a previous study of inducing
APS in mice with anti-cardiolopin antibodies [14]. Pro-
portionally, the common used concentration of immu-
noglobulins-preparations in mice is 20 ug/dosage and the
titer of 20 ug rabbit anti-B19-VP1u IgG is similar to 27 U
after determination and mathematics conversion (IBL-
America, MN, USA) while the values of other control IgG
preparations are less than 7 U. The titer greater than 12 U
is considered as positive. The mice at age of 20 weeks were
divided into four groups and were intravenously received
rabbit anti-B19-VP1u IgG (20 ug), normal rabbit IgG (20
ug), rabbit anti-B19-NS1 IgG (20 ug), and PBS through
the tail vein, respectively. The mice were then sacrificed on
day 30 by CO2 asphyxiation and the heart blood samples
were collected. APS clinical parameters, including throm-
bocytomenia and prolonged activated partial thrombo-
plastin time [aPTT], were evaluated and the platelet
counts were detected using Systemex (KX-21, KOBE,
Japan). The presence of lupus anticoagulants were evalu-
ated by the prolongation of aPTT in a mixing tests by add-
ing 1 volume of plasma from whole blood mixed with
sodium citrate 0.123 mol/l in a 9:1 ratio to 1 volume of
each cephalin and incubating for 2 minutes at 37°C.
Another volume of 0.025 M CaCl2 (Sigma, Saint Louis
Mo, USA) was added, and the clotting time was recorded
in seconds using Coatron M1 (TECO GmbH, Neufahrn
NB, Germany).
ELISA
Direct antigen-specific ELISA kits were used to detect APhL
IgG (Louisville APL Diagnostics, Inc. GA, USA) and anti-
dsDNA IgG (INOVA Diagnostics, Inc. CA, USA) was per-
formed as described in our recent publication [12,13]. The
color reaction was performed as described above. For
detecting the binding activity of anti-B19-VP1u antibody,
recombinant B19-VP1u was coated in a 96 well plate and
ELISA was performed as described in our recent report
[13]. The cutoff value for each ELISA experiment was
obtained (mean+3SD) and the absorbance above the
value is regarded as positive.
Preparation of tissue extract and determination of protein
All procedures were performed at 4°C. Liver samples
obtained from NZB/W F1 mice were homogenized in 600
ul PRO-PREP™ solution (iNtRON Biotech, Korea) by 30
strokes using a Dounce Homogenizer (Knotes Glass, Vine-
land, NJ). The homogenates were centrifuged at 13,000
rpm for 10 minutes at 4°C and the supernatant was stored
at -80°C until use. Protein concentration of tissue extracts
was determined according to the method described by
Bradford [17] using bovine serum albumin as standards.Journal of Biomedical Science 2009, 16:14 http://www.jbiomedsci.com/content/16/1/14
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Gel zymography
MMP-2 and MMP-9 activities were analyzed by gelatin-
zymography assays as previously described [18]. Ten
microliters of ten-fold diluted serum or 25 g protein
lysates of liver tissue from NZB/W F1 mice with passive
transfer anti-idiotype antibodies were separated by an 8%
Sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gels containing 0.1% gelatin. Gels were
washed for 30 min in 2.5% Triton X-100 to remove the
SDS and then soaked in the reaction buffer containing 40
mM Tris-HCl, pH8.0, 10 mM CaCl2 and 0.02% NaN3 for
30 min. The reaction buffer was changed to a fresh one,
and the gels were incubated at 37°C for 24 h. Gelatino-
lytic activity was visualized by staining the gels with 0.5%
Coomassie brillant blue R-250, destained with methanol-
acetic acid water, and relative MMP levels were quanti-
tated by a gel documentation and analysis system
(Appraise, Beckman-Coulter, Brea, California, USA).
Western blot
The loading sample for each lane of Western blot was a
pool of four random selected mice of the same group. Pro-
tein samples were separated in 12.5 or 10% of SDS-PAGE
and electrophoretically transferred to nitrocellulose mem-
brane (Amersham Biosciences, Piscataway, NJ, USA)
according to the method of Towbin [19]. After blocking
with 5% non-fat dry milk in (PBS), antibodies against
MMP2, MMP9, phosphatidylinositol 3-phosphate kinase
(PI3K) and phosphorylated extracellular signal-regulated
kinase 1/2 (p-ERK1/2), and actin (Upstates, Charlottes-
ville, Virginia, USA) were diluted in PBS with 2.5% BSA
and incubated for 1.5 hr with gentle agitation at room
temperature. The membranes were then incubated with
horseradish peroxidase (HRP) conjugated secondary anti-
body. Pierce's Supersignal West Dura HRP Detection Kit
(Pierce Biotechnology Inc., Rockford, IL) was used to
detect the antigen-antibody complexes. The blots were
scanned and quantified by densitometry (Appraise, Beck-
man-Coulter, Brea, California, USA).
Statistical analyses
The paired t test and one-way ANOVA were used to ana-
lyze for statistical significance. A P value < 0.05 was con-
sidered significant.
Results
Enhanced APS-like syndrome in NZB/W F1 by passive 
transfer of purified rabbit anti-B19-VP1u antibody
To clarify the influence of anti-B19-VP1u antibody in dis-
ease activity and development of SLE, we employed and
modified the experimental model as described in our pre-
viously report by immunizing NZB/W F1 mice intrave-
nously with various kinds of purified rabbit IgG. The body
weight and various clinical parameters including, WBC,
RBC, HGB, HCT, MCV, MCH and MCHC revealed no sig-
nificant variation in all groups of mice (Table 1). Notably,
significant decreases of platelet counts and aPTT were
observed in sera from NZB/W F1 mice that were received
purified rabbit anti-B19-VP1u IgG, compared to those
mice that were received normal rabbit IgG, rabbit anti-
B19-NS1 IgG, or PBS, respectively (Table 1). Additionally,
ELISA experiments were performed to elucidate the effect
of anti-B19-VP1u IgG by analyzing the binding activities
of APhL antibodies in NZB/W F1 mice that were received
purified rabbit anti-B19-VP1u IgG. Elevated titers of anti-
B19-VP1u and APhL and anti-dsDNA antibodies were
detected in serum from NZB/W F1 mice that were received
purified rabbit anti-B19-VP1u IgG as compared to those
Table 1: Mice infused with various rabbit antibody or reagent
Antibodies or reagent infused into mice
PBS
[n = 6]
Control IgG
[n = 6]
B19-NS1
[n = 6]
B19-VP1u
[n = 6]
Body Weight (gram) 33.9 ± 1.7 33.9 ± 0.2 32.6 ± 2.5 33.6 ± 2.7
WBC (103 cells/ul) 6.3 ± 0.7 5.5 ± 1.1 6.2 ± 1.6 4.3 ± 1.4
RBC (106 cells/ul) 7.7 ± 0.6 8.7 ± 0.2 8.1 ± 0.2 7.8 ± 0.2
HGB (g/dL) 12.5 ± 1.1 15 ± 0.3 13.6 ± 0.5 13.3 ± 0.6
HCT (%) 44.2 ± 1.3 53.3 ± 2.2 50.4 ± 1.9 47.2 ± 1.4
MCV (fL) 57.3 ± 2.5 61.1 ± 1.1 62.3 ± 0.8 60.4 ± 0.9
MCH (pg) 16.2 ± 0.3 17.2 ± 0.2 16.9 ± 0.3 17.4 ± 0.6
MCHC (g/dL) 28.3 ± 1.7 28.2 ± 0.8 27.1 ± 0.2 28.3 ± 1.3
aPTT (second) 69.5 ± 8.1 76.4 ± 11.6 87 ± 6.0 156 ± 27.0* ,#,¥
Platelet count (103 cells/mm3) 1186 ± 219 1198 ± 124 1374 ± 179 808 ± 90.0* ,#,¥
The unit of the parameter is presented in bracket.
NS1: non-structure protein 1; VP1u: VP1 unique region protein; WBC: white blood cell; RBC: red blood cell; HGB: Hemoglobin; HCT: Hematocrit; 
MCV: Mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: hemoglobin concentration; aPTT: activated partial thromboplastin 
time.
*, #, and ¥ indicate P < 0.05, as compared to the PBS, control IgG, or B19-NS1 group, respectively.Journal of Biomedical Science 2009, 16:14 http://www.jbiomedsci.com/content/16/1/14
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mice that were received normal rabbit IgG, anti-B19-NS1
IgG, or PBS, respectively (Fig. 1).
Enhanced MMP-9 activity and expression in liver from 
NZB/W F1 by passive transfer of purified rabbit anti-B19-
VP1u antibody
To further examine the effect of anti-B19-VP1u antibody
on pathogenesis of liver in NZB/W F1 mice, MMPs activity
and protein expression were examined. Significant
increase of MMP9 activity was observed in liver of NZB/W
F1 mice that were received rabbit anti-B19 VP1u IgG as
compared to PBS, Control IgG, or B19-NS1 IgG group,
respectively (Fig. 2A). However, no significant variation
was detected in MMP-2 activity among all experimental
groups (Fig. 2A). The quantified results of MMP-9/MMP-
2 ratio were shown in lower panel of Fig 2A. Moreover,
Western blots were performed to examine the expression
of MMP9 and MMP2. Significant increase of MMP-9/
MMP-2 ratio was detected in B19-VP1u group as com-
pared to PBS, Control IgG, or B19-NS1 IgG group, respec-
tively (Fig 2B). Quantified results were shown in the lower
panel of Fig 2B.
Increased phosphorylation of ERK 1/2 and PI3K proteins in 
NZB/W F1 by passive transfer of purified rabbitanti-B19-
VP1u antibody
To clarify the possible signaling pathway involved in the
activation of MMP9 by B19-VP1u, various signaling mol-
ecules including, PI3K, Erk1/2-p, p38-p, and JNK-p were
examined. Notably, the PI3K and phosphorylation of ERK
1/2 proteins were observed in liver from NZB/W F1 mice
that were treated with rabbit anti-B19 VP1u IgG, as com-
pared to PBS, Control IgG, or B19-NS1 IgG group, respec-
tively (Fig 3). However, no significant variations of p38-p
and JNK-p were observed in all experimental groups (data
not shown). Quantified results were shown in lower pan-
els of Fig. 3A and 3B.
Discussion
B19 infection has been implicated as a trigger of various
autoimmune diseases including the induction of autoan-
tibodies in patients with SLE [7-11]. However, the roles of
B19-VP1u and anti-B19-VP1u antibody in pathogenesis
of autoimmune diseases remain unclear. In current study,
we demonstrated the aggravated effect of anti-B19-VP1u
antibody on disease activity in SLE by analyzing the APS-
like syndrome. Significant aggravated disease activities,
including reduced platelet count, prolonged thrombocy-
topenia time, increased binding activity of autoantibody,
elevated MMP9 activity and protein expression, were
observed in NZB/W F1 mice that were received anti-B19-
VP1u IgG as compared to those mice that were received
rabbit control IgG, rabbit anti-B19-NS1 IgG or PBS,
respectively.
APS-like syndrome is recognized as a striking analogy
between the clinical features and hematologic findings in
patients with SLE or B19 infection [7-11]. APS is charac-
terized by raised titers of circulating APhL that bind target
molecules primarily via 2GPI, and/or lupus anticoagu-
lant in association with recurrent fetal loss, thromboem-
bolic phenomena, thrombocytopenia, CNS, heart, and
other organ involvement [20,21]. 2GPI shares a com-
mon amino acid sequence with various microbial patho-
gens, and may be the cause of APS or production of the
cross reacting autoantibodies [22-24]. Our previous study
identified four cases of B19 infection associated with the
production of aCL and anti-2GPI antibodies [12]. Con-
sistently, our recent study has demonstrated a spectrum of
experimental APS-like autoimmunity induced by passive
transfer of purified rabbit anti-B19-VP1u IgG antibodies
and provided a connection between anti-B19-VP1u IgG
and pathogenesis of SLE [13]. In current study, we indi-
cated the significant increases of APS-like syndromes
including increased platelet count, prolonged PTT, and
increased binding activity of APhL and dsDNA in NZB/W
F1 mice that were received purified anti-B19-VP1u IgG.
These findings strikingly suggested the aggravated effect of
anti-B19-VP1u IgG in SLE.
Numerous studies have suggested that B19-VP1u plays a
crucial role in induction of anti-2GPI and APhL antibod-
ies [8,9,13]. Adsorption experiment revealed the partially
reduced reactivity of anti-B19-VP1u antibody to CL and
2GPI [12], suggesting similar epitopes or conformation
may exist between B19-VP1u, CL and 2GPI [8,9,12,13].
These experimental results may also account for the cross-
reactivity of anti-B19-VP1u antibody against CL, 2GPI,
and ph ospholipid and suggest underlying mechanisms in
development of APS-like syndrome such as APhL anti-
body. In current study, significant increase of APhL anti-
bodies was observed in NZB/W F1 mice that were received
purified rabbit anti-B19-VP1u IgG, as compared to those
mice that were received control rabbit IgG, rabbit anti-
B19-NS1 IgG or PBS, respectively. This finding may be due
to the similar epitopes and anti-idiotype networks among
anti-B19-VP1u IgG, and APhL antibody. However, the
underlying mechanism is still unclear and deed merited
further investigations.
Previous studies have postulated MMPs to the pathogene-
sis of SLE [25-28]. Cleavage of myelin basic protein or
type II gelatins by MMP-9 will produce remnant epitopes
and contribute to the development of autoimmunity
[27,28]. In recent studies, elevated MMP-9 activity was
founded in both human and mice model with SLE [28-
31] and recognized to play crucial roles in development of
SLE. Additionally, various studies have indicated the
involvement of ERK and PI3K in activation of MMP-9. In
monocytes from patients with rheumatoid arthritis, inhi-Journal of Biomedical Science 2009, 16:14 http://www.jbiomedsci.com/content/16/1/14
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Binding activity of various autoantibodies Figure 1
Binding activity of various autoantibodies. Anti-sera from the 4 groups of mice were analyzed for the binding activities of 
(A) B19-VP1u and (B) PhL, and (C) dsDNA. Bars represent the values of optical density. *, # and ¥ indicate significant differ-
ences as compared to the PBS, IgG, or B19-NS1 group, respectively. Similar results were obtained in three independent exper-
iments.
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Activities and protein expression of MMP-9 andMMP-2 Figure 2
Activities and protein expression of MMP-9 andMMP-2. Liver samples obtained from the 4 groups of mice were ana-
lyzed for the (A) MMP-9 and MMP-2 activity and (B) MMP-9 and MMP-2 protein expression. The quantified results of MMP-9/
MMP-2, MMP-9/actin, and MMP-2/actin ratio were shown in the lower panels, respectively. *, # and ¥ indicate significant differ-
ences as compared to the PBS, IgG, or B19-NS1 group, respectively. Similar results were obtained in three independent exper-
iments.
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Presence of PI3K and phosphorylated ERK proteins Figure 3
Presence of PI3K and phosphorylated ERK proteins. Liver samples obtained from the 4 groups of mice were analyzed 
for the (A) PI3K and (B) phosphorylated ERK (ERK-p) proteins. The quantified results of PI3K/actin and ERK-p/actin ratios 
were shown in the lower panels, respectively. *, # and ¥ indicate significant differences as compared to the PBS, IgG, or B19-
NS1 group, respectively. Similar results were obtained in three independent experiments.
PI3K
Erk-p
anti-VP1u IgG anti-NS1 IgG IgG PBS
anti-VP1u IgG anti-NS1 IgG IgG PBS
A
B
˃
˃ˁˈ
˄
˄ˁˈ
˅
˅ˁˈ
Actin
R
a
t
i
o
 
o
f
 
P
I
3
K
-
p
/
A
c
t
i
n
anti-VP1u 
IgG
anti-NS1 
IgG
IgG PBS
˃
˃ˁˈ
˄
˄ˁˈ
˅
˅ˁˈ
Actin
anti-VP1u 
IgG
anti-NS1 
IgG
IgG PBS
R
a
t
i
o
 
o
f
 
E
r
k
-
p
/
A
c
t
i
n
* #¥
* #¥Journal of Biomedical Science 2009, 16:14 http://www.jbiomedsci.com/content/16/1/14
Page 8 of 9
(page number not for citation purposes)
bition of extracellular signal-regulated kinase (ERK) abol-
ished Cyclosporine A-induced MMP-9 expression [32].
Another study reported that PI3K/Akt activation promotes
transcriptional co-factor p300 recruitment and activation
and led to increased proMMP-9 expression in rat astrocyte
[33]. In current study, significant increases of MMP-9
activity and protein expression were detected in NZB/W
F1 mice that were received anti-B19-VP1u IgG, as well as
the increased PI3K and phosphorylated ERK proteins.
These data suggest the aggravated effect of anti-B19-VP1u
IgG in pathogenesis of SLE and the involvement of activa-
tion of MMP-9 via PI3K and ERK signaling pathway. It
could provide clues in treatment of SLE by inhibiting PI3K
and EKR signaling pathway.
Conclusion
Taken together, our experimental results firstly demon-
strated the aggravated APS-like syndromes in NZB/W F1
mice that were received anti-B19-VP1u IgG. Additionally,
it could provide clues in understanding the roles of anti-
B19-VP1u IgG in SLE and suggest possible therapeutic
potential by inhibiting PI3K or AKT signaling pathway.
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